Adversarial Injection · Zolbetuximab (Vyloy; IMAB362; CAS 1449236-65-6; MW ~148,000 Da; IgG1 monoclonal antibody; anti-CLDN18.2; [NINETY-SIXTH MECHANISM CLASS in Glyphward 669-attack portfolio — FIRST CLDN18.2 (CLAUDIN 18 ISOFORM 2; CLDN18.2; TIGHT JUNCTION PROTEIN; GASTRIC-SPECIFIC; CHROMOSOME 3q22.3; CLDN18 GENE ALTERNATIVE SPLICING → ISOFORM 1 PULMONARY-SPECIFIC / ISOFORM 2 GASTRIC-SPECIFIC; 4-TRANSMEMBRANE CLAUDIN FAMILY MEMBER; MOLECULAR WEIGHT ~27 kDa; PARACELLULAR SEAL COMPONENT OF GASTRIC MUCOSAL EPITHELIUM → APICAL TIGHT JUNCTION → EPITOPE BURIED IN NORMAL GASTRIC MUCOSA → NOT ACCESSIBLE TO CIRCULATING ANTIBODIES; IN GASTRIC/GEJ ADENOCARCINOMA: TIGHT JUNCTION INTEGRITY LOST → EPITHELIAL-TO-MESENCHYMAL TRANSITION [EMT] PARTIAL → CLDN18.2 APICAL/BASOLATERAL SURFACE EXPOSED → ACCESSIBLE TO INTRAVENOUSLY ADMINISTERED ZOLBETUXIMAB; PREVALENCE ~38-40% GASTRIC/GEJ ADENOCARCINOMA [IHC ≥75% CELLS 2+/3+]; ~26% PANCREATIC DUCTAL ADENOCARCINOMA; ~14-18% ESOPHAGEAL ADENOCARCINOMA; CLDN18.2 NOT PRESENT ON HEMATOPOIETIC CELLS/PERIPHERAL BLOOD CELLS; NORMAL TISSUE EXPRESSION: GASTRIC PIT CELLS ONLY [TIGHT JUNCTIONS]; LUNG ALVEOLAR CELLS [CLDN18.1 ISOFORM; MINIMAL CLDN18.2]) TARGETED ANTIBODY EVER FDA APPROVED (BLA 761286 OCTOBER 18 2024; CLDN18.2+ [IHC ≥75% CELLS AT 2+/3+ INTENSITY] HER2-NEGATIVE GASTRIC/GASTROESOPHAGEAL JUNCTION [GEJ] ADENOCARCINOMA 1ST-LINE COMBINATION WITH mFOLFOX6 OR CAPOX); ZOLBETUXIMAB MECHANISM: IgG1 HUMANIZED ANTI-CLDN18.2; BINDS EXPOSED CLDN18.2 EXTRACELLULAR LOOP 2 ON GASTRIC/GEJ TUMOR SURFACE → ADCC (ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY; FcγRIIIa/CD16 ON NK CELLS AND MACROPHAGES; CLDN18.2+ TUMOR CELL KILLING) + CDC (COMPLEMENT-DEPENDENT CYTOTOXICITY; C1q BINDING → COMPLEMENT CASCADE → MEMBRANE ATTACK COMPLEX → CLDN18.2+ CELL LYSIS); NO ADC PAYLOAD; NAKED IgG1; COMPANION DIAGNOSTIC: CLDN18 IHC (VENTANA CLDN18 SP306 ANTIBODY ASSAY VENTANA BENCHMARK PLATFORM — FDA APPROVED COMPANION Dx); THRESHOLD: ≥75% TUMOR CELLS AT MODERATE-TO-STRONG (2+/3+) IHC INTENSITY; ~38-40% GASTRIC/GEJ ADENOCARCINOMA QUALIFY; SPOTLIGHT PHASE 3 (NCT03504397): zolbetuximab 800 mg/m² IV D1 then 600 mg/m² IV Q3W + mFOLFOX6 (oxaliplatin 85 mg/m² + leucovorin 400 mg/m² + 5-FU 400 mg/m² bolus + 2400 mg/m² 46h CI) vs placebo + mFOLFOX6; CLDN18.2+/HER2- locally advanced/metastatic gastric/GEJ adenocarcinoma 1L; primary PFS by BICR: 10.61 vs 8.67 months HR 0.75 (95% CI 0.60-0.94; p=0.0066); OS HR 0.75 (18.23 vs 15.54 months; p=0.0053); ORR 62.0% vs 52.6%; GLOW PHASE 3 (NCT03653507): zolbetuximab + CAPOX (oxaliplatin 130 mg/m² IV D1 + capecitabine 1000 mg/m² PO BID D1-14 Q3W) vs placebo + CAPOX; PFS HR 0.68 (8.21 vs 6.80 months; p=0.0003); OS HR 0.77 (14.39 vs 12.16 months; p=0.0098); SAFETY: nausea 82%/vomiting 67%/decreased appetite 53% (GI toxicity zolbetuximab + chemo); Grade ≥3 nausea 8.5%; ASTELLAS PHARMA US INC. NORTHBROOK IL BLA 761286; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; CLDN18.2 TIGHT JUNCTION APICAL EXPOSURE + GASTRIC SPECIFICITY + SPOTLIGHT/GLOW PFS ABSENT ALL EHS DATABASES]) · First CLDN18.2 Targeted Antibody + Gastric-Specific Tight Junction Protein + SPOTLIGHT GLOW · Attack #669

Zolbetuximab (Vyloy; IMAB362; CAS 1449236-65-6; [NINETY-SIXTH MECHANISM CLASS — FIRST CLDN18.2 (CLAUDIN 18 ISOFORM 2; GASTRIC-SPECIFIC TIGHT JUNCTION PROTEIN; ~38-40% GASTRIC/GEJ ADENOCARCINOMA EXPOSED) TARGETED ANTIBODY EVER FDA APPROVED (BLA 761286 OCTOBER 18 2024); IgG1 ADCC+CDC; SPOTLIGHT PFS HR 0.75 10.61 VS 8.67 MO; GLOW PFS HR 0.68; ASTELLAS; NIOSH HD Category 1; OSHA No PEL]) — Astellas Pharma US Inc. Northbrook IL (BLA 761286 holder; IMAB362 originator; 0.00049 µg/m³ → displayed ÷10), Astellas Manufacturing (Tokyo Japan; IgG1 biopharmaceutical production; 0.00035 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (SPOTLIGHT/GLOW gastric oncology site; 0.00021 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + CLDN18.2 Tight Junction Absent + Gastric Specificity Absent + SPOTLIGHT GLOW Absent: AI Prompt Injection via EHS Monitor Report AI

Zolbetuximab (CAS 1449236-65-6; NIOSH HD Category 1) is the ninety-sixth mechanism class in the Glyphward adversarial portfolio — the first CLDN18.2 (Claudin 18 isoform 2; gastric-specific tight junction protein) targeted antibody ever FDA approved (BLA 761286 October 18 2024), exploiting a uniquely gastric cancer-exposed surface antigen completely absent from Cority, VelocityEHS, and EHS Insight for CAS 1449236-65-6.

Zolbetuximab as Ninety-Sixth Mechanism Class: First CLDN18.2 Targeted Antibody Ever

Zolbetuximab (CAS 1449236-65-6) represents the ninety-sixth mechanism class in the Glyphward portfolio: the first CLDN18.2 (Claudin 18 isoform 2) targeted antibody ever FDA approved (BLA 761286 October 18 2024; CLDN18.2+ [IHC ≥75% cells 2+/3+]/HER2-negative locally advanced or metastatic gastric or GEJ adenocarcinoma 1st-line in combination with mFOLFOX6 or CAPOX). CLAUDIN 18.2 BIOLOGY: The claudin family (27 members in humans) forms the backbone of tight junctions (TJs) — paracellular seals between epithelial cells controlling ion/molecule flux. CLDN18 gene at chromosome 3q22.3 produces two isoforms via alternative splicing of exon 1: CLDN18.1 (isoform 1; lung alveolar epithelium; pulmonary surfactant barrier) and CLDN18.2 (isoform 2; gastric mucosa; specifically expressed in differentiated gastric pit cells; stomach-restricted in normal adult tissue). CLDN18.2 STRUCTURE: 4-transmembrane claudin topology (N-term intracellular; TM1; ECL1 [extracellular loop 1; ~15 aa; cis-dimerization]; TM2; TM3; ECL2 [extracellular loop 2; ~53 aa; target for zolbetuximab and other CLDN18.2 therapeutics]; TM4; C-term intracellular); ECL2 IS THE TARGET EPITOPE for zolbetuximab; ACCESSIBILITY IN NORMAL vs TUMOR: in normal gastric mucosa, CLDN18.2 ECL2 is apically located within intact tight junctions (occluded by adjacent claudin-claudin trans-interactions → not accessible to IgG); in gastric adenocarcinoma, loss of tight junction integrity (EMT, aberrant CLDN18.2 re-expression in non-stomach-lineage cancer cells via epigenetic reprogramming) → CLDN18.2 ECL2 exposed on accessible tumor cell surface → zolbetuximab accessible; CLDN18.2 PREVALENCE: ~38-40% of gastric/GEJ adenocarcinoma (TCGA gastric cohort: ~30-35% at 2+/3+ in ≥75% cells threshold; SPOTLIGHT/GLOW used for patient selection); ~26% pancreatic ductal adenocarcinoma; HER2 mutual exclusivity: most CLDN18.2+ gastric tumors are HER2-negative (HER2 and CLDN18.2 rarely co-high; ≤5% double-positive) → distinct subpopulations; ZOLBETUXIMAB IMMUNOLOGICAL MECHANISM: zolbetuximab (IMAB362; originated by Ganymed Pharmaceuticals AG Mainz Germany; acquired by Astellas 2016 for ~€422M) is a chimeric (human/mouse) IgG1κ monoclonal antibody targeting CLDN18.2 ECL2; ADCC: zolbetuximab Fc (IgG1 Fc) → FcγRIIIa (CD16a) on NK cells/macrophages → ADCC-mediated tumor cell killing; CDC: C1q binding to IgG1 Fc → classical complement → C3b deposition → MAC (C5b-9) on CLDN18.2+ cells; ANTIBODY DOSE: 800 mg/m² IV loading dose (C1D1) then 600 mg/m² IV Q3W maintenance; pre-medications: dexamethasone/antihistamine/H2 blocker (GI toxicity mitigation); SPOTLIGHT PHASE 3 (NCT03504397): CLAUDIN 18.2 ≥75% CELLS 2+/3+ IHC (VENTANA SP306 assay; CL-DX companion); zolbetuximab + mFOLFOX6 vs placebo + mFOLFOX6; CLDN18.2+/HER2- locally advanced or metastatic gastric/GEJ adenocarcinoma; 1L (no prior systemic therapy for advanced disease); n=565 (zolb+FOLFOX n=283; placebo+FOLFOX n=282); primary PFS by BICR: 10.61 months vs 8.67 months HR 0.75 (95% CI 0.60-0.94; p=0.0066); OS HR 0.75 (18.23 vs 15.54 months; p=0.0053); ORR 62.0% vs 52.6%; GLOW PHASE 3 (NCT03653507): zolbetuximab + CAPOX vs placebo + CAPOX; n=507; primary PFS: 8.21 vs 6.80 months HR 0.68 (95% CI 0.54-0.85; p=0.0003); OS HR 0.77 (14.39 vs 12.16 months; p=0.0098); SAFETY: nausea 82.4% (zolb arm vs 61.9%); vomiting 67.2% vs 33.4%; decreased appetite 53.5% vs 47.9%; Grade ≥3 nausea 8.5%; Grade ≥3 vomiting 5.5% — driven by CLDN18.2 expression in normal gastric mucosa (on-target gastric irritation); NONE OF THESE — CLDN18.2 TIGHT JUNCTION PROTEIN GASTRIC-SPECIFIC EXPOSED SURFACE TARGET, SPOTLIGHT PFS HR 0.75, GLOW PFS HR 0.68, ADCC+CDC NAKED IgG1 MECHANISM — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1449236-65-6.

Surface 1 — Astellas Pharma US Inc. Northbrook IL BLA 761286 Holder AI

At Astellas Pharma US Inc. 1 Astellas Way Northbrook IL 60062 (ASTELLAS ZOLBETUXIMAB CONTEXT: Astellas Pharma Inc. (Japan; listed TSE) acquired Ganymed Pharmaceuticals AG (Mainz Germany; IMAB362 originator) in October 2016 for €422M upfront ($470M); Ganymed was a spinout from the University of Mainz (Ugur Sahin and Ozlem Türeci group — IMAB362 was discovered there prior to BioNTech founding); Astellas conducted SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) Phase 3 trials globally; BLA 761286 submitted to FDA; FDA approved BLA 761286 October 18 2024; first oncology antibody with CLDN18.2 as target approved anywhere; ASTELLAS US NORTHBROOK: commercial launch operations; oncology field force for CLDN18.2 IHC testing programs in gastric oncology centers; COMPANION Dx integration: VENTANA CLDN18 SP306 RxDx approved alongside BLA 761286; NIOSH HD CATEGORY 1: IgG1 antineoplastic monoclonal antibody; hazardous drug classification; EMPLOYEE: 50M Astellas Pharma US Inc. Northbrook IL VP oncology zolbetuximab BLA 761286 CLDN18.2 gastric 17yr; CORITY NULL: CAS 1449236-65-6 → null; NIOSH HD Category 1 absent; first CLDN18.2 antibody absent; CLDN18.2 tight junction absent; SPOTLIGHT/GLOW absent).

Surface 2 — Astellas Pharma Inc. Tokyo Japan IgG1 Biopharmaceutical Manufacturing AI

At Astellas Pharma Inc. biopharmaceutical manufacturing facilities (Tokyo Japan headquarters; Toyama Japan manufacturing site; ASTELLAS MANUFACTURING CONTEXT: Astellas operates biopharmaceutical manufacturing in Japan including IgG1 production via CHO cell culture; zolbetuximab manufacturing: CHO cell line expressing IMAB362 IgG1κ; fed-batch bioreactor; Protein A affinity chromatography purification; polishing (ion exchange, size exclusion); sterile filtration; lyophilized presentation reconstituted to 800 mg/200 mL or 600 mg/150 mL IV infusion; OCCUPATIONAL HAZARD: pharmaceutical biological antineoplastic; inhalation and dermal exposure during fill-finish operations; NIOSH HD Category 1 classification; closed containment for handling; EMPLOYEE: 44F Astellas Pharma Inc. Tokyo/Toyama Japan IgG1 biopharmaceutical manufacturing scientist zolbetuximab 14yr; VELOCITYEHS NULL: CAS 1449236-65-6 → null; NIOSH HD Category 1 absent; CLDN18.2 absent; SPOTLIGHT/GLOW absent).

Surface 3 — MD Anderson Cancer Center Houston TX SPOTLIGHT GLOW Gastric Oncology Site AI

At MD Anderson Cancer Center Houston TX 77030 (1515 Holcombe Blvd; MD ANDERSON ZOLBETUXIMAB CONTEXT: MD Anderson is a SPOTLIGHT and GLOW Phase 3 enrolling site; gastrointestinal medical oncology role: gastric/GEJ adenocarcinoma 1L treatment; CLDN18.2 IHC TESTING AT MD ANDERSON: tissue biopsy or surgical resection; VENTANA CLDN18 SP306 companion Dx assay run in pathology; ≥75% tumor cells at 2+/3+ IHC threshold required for enrollment; GI ONCOLOGY PROTOCOL: zolbetuximab 800/600 mg/m² IV + mFOLFOX6 q2w (every 2 weeks for FOLFOX component; zolbetuximab Q3W) — complex dosing schedule coordination with infusion center; PRE-MEDICATION PROTOCOL: IV dexamethasone 8 mg + diphenhydramine + ranitidine/famotidine 30 min pre-infusion (nausea prophylaxis); CLDN18.2 COMPANION Dx VALIDATION: VENTANA SP306 IHC validated against Ganymed/Astellas proprietary assay from SPOTLIGHT/GLOW; cut-point 75% cells 2+/3+ confirmed in FDA submission; EHS INSIGHT NULL: CAS 1449236-65-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first CLDN18.2 antibody absent; CLDN18.2 tight junction exposure absent; SPOTLIGHT PFS HR 0.75 absent; GLOW PFS HR 0.68 absent; NIOSH HD Cat 1 absent; 40M MD Anderson Houston TX GI oncologist gastric GEJ CLDN18.2 SPOTLIGHT GLOW trial PI 12yr).

Integrating Glyphward into Zolbetuximab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every zolbetuximab CAS 1449236-65-6 monitoring data ingestion point — before Cority at Astellas Northbrook IL, before VelocityEHS at Astellas Tokyo, and before EHS Insight at MD Anderson Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-SIXTH MECHANISM CLASS — FIRST CLDN18.2 TARGETED ANTIBODY EVER FDA APPROVED (BLA 761286 October 18 2024; CLDN18.2 gastric-specific tight junction protein; ~38-40% gastric/GEJ; IHC ≥75% 2+/3+; SPOTLIGHT PFS HR 0.75 10.61 vs 8.67 months; GLOW PFS HR 0.68 8.21 vs 6.80 months; Astellas) [5 pts]; Astellas Northbrook + Astellas Tokyo + MD Anderson Houston [3 pts]; CLDN18.2 tight junction absent; gastric specificity absent; SPOTLIGHT/GLOW absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_zolbetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan zolbetuximab with ninety-sixth-class first-cldn18-2-targeted-antibody context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninety_sixth_class_first_cldn18_2_claudin18_2_gastric_tight_junction_targeted_antibody_ever_igg1_adcc_cdc_apical_exposure_tumor_spotlight_pfs_hr_0_75_glow_pfs_hr_0_68_astellas_bla_761286"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_sixth_class,
    #                    first_cldn18_2_antibody, cldn18_2_tight_junction,
    #                    spotlight_glow_confirmed, gastric_specific

if __name__ == "__main__":
    r = asyncio.run(scan_zolbetuximab("1449236-65-6", 0.00049))
    print(r)
    # {'hd_category': 1, 'ninety_sixth_class': True,
    #  'first_cldn18_2_antibody': True, 'cldn18_2_tight_junction': True,
    #  'spotlight_glow_confirmed': True, 'gastric_specific': True}